Tectonic Therapeutic (TECX) CEO-linked family trust buys 2,500 shares

Rhea-AI Filing Summary

Tectonic Therapeutic, Inc. director and Chief Executive Officer Alise Reicin reported that the Reicin-Boiarsky Family Trust, a trust associated with her, bought 2,500 shares of common stock in an open-market purchase on February 11, 2026 at a weighted average price of $21.10 per share.

Following this transaction, the trust holds 127,030 shares with indirect ownership attributed to Reicin, while she also directly owns 235,047 shares of common stock.

Insider Trade Summary

Net Buyer: 2,500 shares ($52,750)

Net Buy 2 txns

Insider REICIN ALISE

Role Chief Executive Officer

Bought 2,500 shs ($53K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	2,500	$21.10	$53K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 127,030 shares (Indirect, By Trust); Common Stock — 235,047 shares (Direct)

Footnotes (1)

1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $21.02 to $21.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. These shares are held by the Reicin-Boiarsky Family Trust (the "Trust"). The Reporting Person's spouse is a co-trustee of the Trust. Accordingly, the Reporting Person may be deemed to have shared voting and dispositive power over the securities held by the Trust. The Reporting Person disclaims beneficial ownership of the shares held by the Trust except to the extent of her pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

REICIN ALISE

(Last) (First) (Middle)

C/O TECTONIC THERAPEUTIC, INC.

490 ARSENAL WAY, SUITE 200

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Tectonic Therapeutic, Inc. [ TECX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)
02/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/11/2026		P		2,500	A	$21.1(1)	127,030	I	By Trust(2)
Common Stock								235,047	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $21.02 to $21.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

2. These shares are held by the Reicin-Boiarsky Family Trust (the "Trust"). The Reporting Person's spouse is a co-trustee of the Trust. Accordingly, the Reporting Person may be deemed to have shared voting and dispositive power over the securities held by the Trust. The Reporting Person disclaims beneficial ownership of the shares held by the Trust except to the extent of her pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Remarks:

This Form 4/A is being filed to correct the Form 4 filed with the Securities and Exchange Commission on February 12, 2026 (the "Original Filing Date"). The Reporting Person's Trust purchased the shares reported in the Form 4 filed on the Original Filing Date, not the Reporting Person directly. This Form 4 reflects the correct ownership of the Reporting Person and the Trust as of the Original Filing Date.

	/s/ Daniel Lochner, Attorney-in-Fact	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Tectonic Therapeutic (TECX) report for Alise Reicin?

Tectonic Therapeutic reported that a trust associated with CEO and director Alise Reicin bought 2,500 shares of common stock in an open-market purchase on February 11, 2026, at a weighted average price of about $21.10 per share.

How many Tectonic Therapeutic (TECX) shares did the Reicin-Boiarsky Family Trust buy?

The Reicin-Boiarsky Family Trust acquired 2,500 shares of Tectonic Therapeutic common stock. This was an open-market purchase, with the reported weighted average purchase price of approximately $21.10 per share, based on individual trades between $21.02 and $21.15.

At what prices were the Tectonic Therapeutic (TECX) insider shares purchased?

The insider-related trust purchase used a weighted average price of about $21.10 per Tectonic Therapeutic share. Individual trades that make up this average occurred in a price range from $21.02 to $21.15, according to the Form 4/A disclosure footnote.

How many Tectonic Therapeutic (TECX) shares does the Reicin-Boiarsky Family Trust hold after the trade?

After the reported open-market purchase, the Reicin-Boiarsky Family Trust holds 127,030 shares of Tectonic Therapeutic common stock. These shares are reported as indirect ownership for CEO Alise Reicin, reflecting her relationship to the trust and its co-trustee structure.

What is Alise Reicin’s direct share ownership in Tectonic Therapeutic (TECX)?

Separate from the trust holdings, CEO and director Alise Reicin directly owns 235,047 shares of Tectonic Therapeutic common stock. This direct position is reported alongside her indirect interest in the Reicin-Boiarsky Family Trust’s 127,030 shares.

How does the Form 4/A describe Alise Reicin’s interest in the Reicin-Boiarsky Family Trust?

The filing explains that the Reicin-Boiarsky Family Trust holds the purchased shares, with Reicin’s spouse as co-trustee. Reicin may share voting and dispositive power, but disclaims beneficial ownership beyond her pecuniary interest in the trust’s Tectonic Therapeutic shares.